Abstract
purpose. Eyes with age-related macular degeneration (AMD) demonstrate accumulation of specific deposits and extracellular matrix (ECM) molecules under the retinal pigment epithelium (RPE). Metalloproteinases (MMP) are crucial regulators of basement membrane and ECM turnover. Accordingly, loss of RPE MMP activity most likely leads to excessive accumulation of collagen and other ECM, a potential mechanism for formation of deposits. A prior study showed that MMP-2 activity, but not pro-MMP-2 protein, decreases after RPE oxidative injury, indicating that oxidant injury disrupts the enzymatic cleavage of pro-MMP-2. Activation of MMP-2 requires the formation of a tri-molecular complex of pro-MMP-2, MMP-14, and tissue inhibitor of metalloproteinases (TIMP)-2. Therefore, a study was conducted to investigate the impact of oxidant injury on the interaction between these three molecules.
methods. Human GFP-RPE cells were oxidant injured by transient exposure to H2O2 and myeloperoxidase, and the time course of recovery determined. Supernatants and cell lysates were collected for analysis of MMP-2, MMP-14, and TIMP-2 activity, mRNA and protein expression. In some studies, overexpression with either MMP-14 or TIMP-2 was performed to revert the cells to a preinjury phenotype.
results. Transient injury resulted in a decrease of both MMP-14 and TIMP-2 activity and protein. Overexpression of each single molecule failed to prevent the injury-induced decrease of MMP-2 activity. In contrast, overexpression of MMP-14 together with the addition of exogenous TIMP-2 prevented the reduction of MMP-2 activation.
conclusions. Loss of MMP-2 activity after oxidant injury is caused by the downregulation of MMP-14 and TIMP-2. Overexpression of either MMP-14 or TIMP-2 alone before oxidant injury is not enough to prevent loss of MMP-2 activity. All three components of the tri-molecular complex must be present to preserve normal MMP-2 activity after oxidant injury.
Age-related macular degeneration (AMD) is the most important cause of lost central vision in the elderly.
1 Histopathology of early AMD demonstrates accumulation of specific lipid-rich deposits under the retinal pigmented epithelium (RPE). Many reports have suggested a role for oxidant injury to the RPE as a putative mechanism for AMD pathogenesis, and several different potential oxidants have been suggested, such as those induced by light exposure, endogenous metabolism, and inflammatory cells. We hypothesize that two specific “nonlethal” injury responses are especially relevant to early deposit formation in AMD. In previous studies, we have demonstrated that oxidant injury to the RPE causes nonlethal blebbing, characterized by extrusion of cell membrane and cytosol. However, dysregulated production and breakdown of extracellular matrix (ECM) components in Bruch’s membrane is another specific injury response relevant to AMD.
The normal anatomy and physiology of ECM in most tissues requires continuous turnover of collagen and other matrix components by a tightly regulated balance in production of such matrix molecules as collagen IV, matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs).
2 Relatively small dysregulation of the ratio of these factors can produce profound changes in the ECM, including thickening and deposit formation.
We and others have shown that RPE expresses high levels of MMP-2, a gelatinase important for degradation of collagen IV, fibronectin, and other matrix components relevant to Bruch’s membrane and sub-RPE deposit formation.
3 4 5 6 In recent work, we have shown that transient nonlethal RPE injury with the macrophage-derived pro-oxidant enzyme, myeloperoxidase (MPO), plus its substrate, hydrogen peroxide, results in cell membrane blebbing associated with increased release of pro-MMP-2 from the cell surface, but decreased activation of pro-MMP-2 into the active form.
7 Because most MMPs, including MMP-2, are synthesized as pro molecules that require posttranslational cleavage to produce maximum enzymatic activity, oxidant injury may alter production, expression, or activity of enzyme regulators of MMP activation, to explain the decrease in MMP-2 activity.
Two important regulators of pro-MMP activation include membrane type 1 matrix metalloproteinase (MT1-MMP or MMP-14), and tissue inhibitor of metalloproteinases (TIMP-2).
8 9 Active cell surface bound MMP-14 binds the aminoterminal domain of TIMP-2 whereas its carboxyl terminal domain interacts with pro-MMP-2.
10 Activation of the tethered pro-MMP-2 is executed by a second active MMP-14. Conversely, binding of a second TIMP-2 results in inhibition of pro-MMP activation by MMP-14. Because we and others have shown that RPE expresses high levels of pro-MMP-2, active MMP-2, and TIMP-2,
3 4 5 6 11 we investigated whether MMP-14 is expressed in RPE cells and whether MMP-14 and TIMP-2 mRNA and protein expression are altered after oxidant injury, as a mechanism for changes in MMP-2 activation.
We found that both MMP-14 and TIMP-2 mRNA and protein were expressed and active on noninjured cultured RPE cells. Six to 8 hours after removal of transient oxidative injury, both MMP-14 and TIMP-2 protein expression and activity decreased, resulting in decreased MMP-2 activation. The changes returned to normal by 96 hours after removal of oxidant injury. Of importance, transfection studies revealed that both MMP-14 and TIMP-2 were necessary to prevent oxidant-mediated loss of MMP-2 activation. Loss of regulation of MMP activation may contribute to AMD pathophysiology, and these molecules may be targets for therapeutic intervention.
AMD, the most important cause of central vision loss in the elderly, is characterized by progressive thickening and accumulation of ECM deposits under the RPE.
1 18 We have previously shown that loss of RPE MMP-2 activity correlates with deposit severity in vivo when mice are exposed to blue light, a surrogate for sunlight and acute oxidant injury.
19 We therefore hypothesized that dysregulated production of MMP-2 after oxidant injury could contribute to matrix accumulation. The regulation of MMP-2 activation is well studied in other tissues; however, little information is available regarding MMP-2 activation in human GFP-RPE cells.
5 7
Activation of MMP-2 is a membrane associated event requiring the presence of TIMP-2 and surface MMP-14 binding. This complex acts as a receptor for pro-MMP-2 and subsequent conversion to its active form. In this study, we demonstrated that GFP-RPE cells have active MMP-14 on the cell surface and that it is required for MMP-2 activation. Although the presence of MMP-14 has been reported in human RPE cells,
4 20 to our knowledge, there have been no reports of its ability to activate MMP-2 in vitro in retinal epithelial cells. Because TIMP-2 performs dual roles of either promoting or inhibiting activation of MMP-2, we also investigated its presence in human RPE cells. We were able to detect TIMP-2 protein by Western analysis and reverse zymography, as previously reported in rat and human RPE cells.
6 21
To mimic an oxidant-mediated injury relevant to AMD, we exposed the cells to MPO/H2O2. MMP-14 protein expression and activity were significantly decreased to 50% of control 6 hours after injury and correlated with a decrease of MMP-2 activity. Not unexpectedly, TIMP-2 activity and protein expression were also significantly decreased by 6 hours.
Regulation of MMPs is controlled by gene transcription, activation of pro-MMPs, and interaction of secreted MMPs with inhibitors.
22 Therefore, time course experiments were performed to assess transcriptional and translational responses to injury. We found the maximum decrease in MMP-14 activity and protein expression at 48 hours, at which time recovery began and returned to near baseline levels by 96 hours. Of note, mRNA expression began to increase at 20 hours before recovery of activity. These data partially confirm that the injury, although limited to the cell surface, was not merely damaging cell surface–associated proteins.
MMP-14 activity is crucial for both physiological and disease processes. It was initially identified as the activator of MMP-2,
8 23 but recently has been shown to be essential for wound healing, angiogenesis, and inflammation
24 . It is overexpressed in cancers leading to migration, invasion, and metastasis.
25 MMP-14 activation occurs via a proprotein convertase,
26 27 and recent data suggest that its function is modified by glycosylation, internalization, and recycling.
28 29 Finally, MMP-14 directly degrades ECM molecules including collagen type I and III, laminin, and fibronectin.
30 31 MMP-14 in our system clearly plays a crucial role in regulating MMP-2 and subsequent ECM changes, although its direct influence on accumulation of deposits in AMD remain to be explored in future experiments.
TIMP-2 protein and activity recovered in a coordinate manner, although in our experiments, activity levels never fully reached control levels. Despite this, TIMP-2 activity was sufficient to form a ternary complex with pro-MMP-2 and MMP-14 and to promote recovery of MMP-2 activity.
TIMP-2 has a dual role as mediator of activation and inhibitor of MMP-2.
32 Translational regulation of TIMP-2 is not well described, as its expression is constitutive. Sp1 and NF-Y have been shown to be involved in a cAMP-dependent TIMP-2 gene transcription activation.
33 Yamamoto et al.
34 showed that oxidant injury to an RPE cell line increased cAMP production 36 hours later, which could lead to increased TIMP-2 gene expression. This appears consistent with our mRNA expression data. Alternatively, TNFα activation of the ERK-MAPK pathway after oxidant injury may play a role in TIMP-2 protein regulation. Alexander and Acott
35 showed that treatment of human and porcine trabecular cells with TNFα increases MMP expression but decreases TIMP-2 activity. This finding may be relevant, as oxidative stress has been shown to cause ERK activation in RPE cells.
36
It is likely that the amount of TIMP-2 protein produced after injury is precisely regulated for the RPE to maintain ECM balance. In fact it has been proposed for TIMP-1, that there is an exquisite equilibrium between the rate of mRNA degradation and the rate of translational initiation and elongation.
To further test our hypothesis that MMP-2 changes occur due to changes in its regulator molecules, we transiently transfected human RPE cells to overexpress MMP-14 before oxidant injury. Overexpression of MMP-14 prevented the injury-induced decrease in MMP-14 activity and protein, but did not prevent the injury-induced decrease in MMP-2 activity. Therefore, we pretreated transfected cells with increasing concentrations of recombinant TIMP-2 and found that both MMP-14 and TIMP-2 were necessary to restore MMP-2 activation to preinjury levels. This effect of TIMP-2 was concentration dependent. When we induced overexpression of TIMP-2, we were unable to restore MMP-2 activity after injury, even with the addition of recombinant MMP-14. We presume that in our system overexpression of TIMP-2 produced a ratio of MMP-14 to TIMP-2 that favored inhibition rather than activation of MMP-2. These paradoxical effects of TIMP-2 have been shown in other cell types, and it appears that, in RPE cells as well, prevention of dysregulation of ECM requires a precise ratio of MMP-14 to TIMP-2.
A recent report eloquently showed that there is an alternative pathway for MMP-2 activation through another surface MMP, MMP-15, which is TIMP-2 independent.
37 The expression of MMP-15 has been reported in human RPE cells, but in our studies this molecule clearly did not compensate for the lack of MMP-14 and TIMP-2 after injury.
4
Although there have been reports of other MMP and TIMP molecules produced by RPE cells, we focused on the components of the tri-molecular complex. In fact, MMP-14 was found to be the most abundant molecule in microarray analysis of human RPE samples.
21 This does not exclude the relevance of RPE synthesized MMP-9 and TIMP-1, which are regulated when exposed to cytokines.
4 In fact, we detected a decrease in TIMP-1 activity by reverse zymography (data not shown) after injury. In addition, we were able to visualize TIMP-3, although there were no changes in activity after injury. Mutations in the gene for TIMP-3 cause Sorsby’s fundus dystrophy, a degenerative disease of the macula,
38 and possible implications for its role in wet AMD have been suggested.
39
We propose that in dry AMD RPE injury or stimulation with macrophage-derived factors, especially MPO and TNF-α lead to dysregulated RPE production of matrix molecules that may influence turnover of Bruch’s membrane, accumulation of deposits, and development of corneal neovascularization. Prevention of dysregulation of the components of the tri-molecular complex may lead to development of therapeutic interventions.
Supported in part by National Eye Institute Grant R01 EY14477-02 (SE, SWC).
Submitted for publication September 23, 2005; revised December 15, 2005, and January 3, 2006; accepted February 21, 2006.
Disclosure:
S. Elliot, None;
P. Catanuto, None;
W. Stetler-Stevenson, None;
S.W. Cousins, None
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be marked “
advertisement” in accordance with 18 U.S.C. §1734 solely to indicate this fact.
Corresponding author: Sharon Elliot, Vascular Biology Institute, Miller School of Medicine, 1600 NW 10th Avenue, RSMB 1043, R104, Miami, FL 33136;
[email protected].
Table 1. Time Course of Recovery of MMP-2, MMP-14, and TIMP-2 Activity
Table 1. Time Course of Recovery of MMP-2, MMP-14, and TIMP-2 Activity
Time after Removal of Oxidant Injury (h) | % of Control Activity MMP-2 | % of Control Activity MMP-14 | % of Control Activity TIMP-2 |
6 | 38 ± 12 | 77 ± 18 | ND |
20 | 73 ± 16 | 49 ± 26 | 70 ± 4.5 |
48 | 81 ± 16 | 68 ± 0.2 | 72 ± 10 |
72 | 78 ± 13 | 81 ± 13 | 78 ± 2.3 |
96 | NC | 84 ± 17 | 66 ± 7.9 |
Table 2. Time Course of Recovery of MMP-2, MMP-14, and TIMP-2 Protein Expression
Table 2. Time Course of Recovery of MMP-2, MMP-14, and TIMP-2 Protein Expression
Time after Removal of Oxidant Injury (h) | % of Control Protein Content MMP-2 | % of Control in Protein Content MMP-14 | % of Control Protein Content TIMP-2 |
6 | 64 ± 0.8 | 51 ± 3.7 | 75 ± 15 |
20 | 87 ± 1.2 | ND | 63 ± 2 |
48 | NC | 62 ± 24 | 70 ± 15 |
72 | ND | 85 ± 1.4 | 66 ± 14 |
96 | NC | 92 ± 7.7 | 91 ± 8 |
Table 3. Time Course of Recovery of MMP-2, MMP-14, and TIMP-2 mRNA Expression
Table 3. Time Course of Recovery of MMP-2, MMP-14, and TIMP-2 mRNA Expression
Time after Removal of Oxidant Injury (h) | % of Control mRNA Content MMP-2 | % of Control mRNA Content MMP-14 | % of Control in mRNA Content TIMP-2 |
6 | ND | ND | ND |
20 | 55 ± 13 | 76 ± 14 | 61 ± 18 |
48 | 77 ± 13 | 70 ± 24 | 72 ± 15 |
72 | 70 ± 19 | NC | 75 ± 27 |
BergerJW, FineSL, MaguireMG. Age-Related Macular Degeneration. 1999;Mosby St. Louis.
CorcoranML, HewittRE, KleinerDE, Jr, Stetler-StevensonWG. MMP-2: expression, activation and inhibition. Enzyme Protein. 1996;49:7–19.
[PubMed]AhirA, GuoL, HussainAA, MarshallJ. Expression of metalloproteinases from human retinal pigment epithelial cells and their effects on the hydraulic conductivity of Bruch’s membrane. Invest Ophthalmol Vis Sci. 2002;43:458–465.
[PubMed]EichlerW, FriedrichsU, ThiesA, TratzC, WiedemannP. Modulation of matrix metalloproteinase and TIMP-1 expression by cytokines in human RPE cells. Invest Ophthalmol Vis Sci. 2002;43:2767–2773.
[PubMed]Marin-CastanoME, ElliotSJ, PotierM, et al. Regulation of estrogen receptors and MMP-2 expression by estrogens in human retinal pigment epithelium. Invest Ophthalmol Vis Sci. 2003;44:50–59.
[CrossRef] [PubMed]PadgettLC, LuiGM, WerbZ, LaVailMM. Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 in the retinal pigment epithelium and interphotoreceptor matrix: vectorial secretion and regulation. Exp Eye Res. 1997;64:927–938.
[CrossRef] [PubMed]Marin-CastanoME, CsakyK, CousinsSW. Nonlethal oxidant injury to human retinal pigment epithelium cells causes cell membrane blebbing but decreased MMP-2 activity. Invest Ophthalmol Vis Sci. 2005;46:3331–3340.
[CrossRef] [PubMed]StronginAY, CollierI, BannikovG, MarmerBL, GrantGA, GoldbergGI. Mechanism of cell surface activation of 72-kDa type IV collagenase: isolation of the activated form of the membrane metalloprotease. J Biol Chem. 1995;270:5331–5338.
[CrossRef] [PubMed]KinoshitaT, SatoH, OkadaA, et al. TIMP-2 promotes activation of progelatinase A by membrane-type 1 matrix metalloproteinase immobilized on agarose beads. J Biol Chem. 1998;273:16098–16103.
[CrossRef] [PubMed]SternlichtMD, WerbZ. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol. 2001;17:463–516.
[CrossRef] [PubMed]KameiM, HollyfieldJG. TIMP-3 in Bruch’s membrane: changes during aging and in age-related macular degeneration. Invest Ophthalmol Vis Sci. 1999;40:2367–2375.
[PubMed]StrunnikovaN, BaffiJ, GonzalezA, SilkW, CousinsSW, CsakyKG. Regulated heat shock protein 27 expression in human retinal pigment epithelium. Invest Ophthalmol Vis Sci. 2001;42:2130–2138.
[PubMed]ElliotSJ, StrikerLJ, Stetler-StevensonWG, JacotTA, StrikerGE. Pentosan polysulfate decreases proliferation and net extracellular matrix production in mouse mesangial cells. J Am Soc Nephrol. 1999;10:62–68.
[PubMed]PotierM, ElliotSJ, TackI, et al. Expression and regulation of estrogen receptors in mesangial cells: influence on matrix metalloproteinase-9. J Am Soc Nephrol. 2001;12:241–251.
[PubMed]DahanM, NawrockiB, ElkaimR, et al. Expression of matrix metalloproteinases in healthy and diseased human gingiva. J Clin Periodontol. 2001;28:128–136.
[CrossRef] [PubMed]SunHB, YokotaH. Reduction of cytokine-induced expression and activity of MMP-1 and MMP-13 by mechanical strain in MH7A rheumatoid synovial cells. Matrix Biol. 2002;21:263–270.
[CrossRef] [PubMed]HiraokaN, AllenE, ApelIJ, GyetkoMR, WeissSJ. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell. 1998;95:365–377.
[CrossRef] [PubMed]GreenWR. Histopathology of age-related macular degeneration. Mol Vis. 1999;5:27.
[PubMed]CousinsSW, Espinosa-HeidmannDG, AlexandridouA, SallJ, DubovyS, CsakyK. The role of aging, high fat diet and blue light exposure in an experimental mouse model for basal laminar deposit formation. Exp Eye Res. 2002;75:543–553.
[CrossRef] [PubMed]SmineA, PlantnerJJ. Membrane type-1 matrix metalloproteinase in human ocular tissues. Curr Eye Res. 1997;16:925–929.
[CrossRef] [PubMed]LeuST, BatniS, RadekeMJ, JohnsonLV, AndersonDH, CleggDO. Drusen are cold spots for proteolysis: expression of matrix metalloproteinases and their tissue inhibitor proteins in age-related macular degeneration. Exp Eye Res. 2002;74:141–154.
[CrossRef] [PubMed]JonesCB, SaneDC, HerringtonDM. Matrix metalloproteinases: a review of their structure and role in acute coronary syndrome. Cardiovasc Res. 2003;59:812–823.
[CrossRef] [PubMed]SatoH, TakinoT, OkadaY, et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature. 1994;370:61–65.
[CrossRef] [PubMed]ZuckerS, PeiD, CaoJ, Lopez-OtinC. Membrane type-matrix metalloproteinases (MT-MMP). Curr Top Dev Biol. 2003;54:1–74.
[PubMed]SeikiM, YanaI. Roles of pericellular proteolysis by membrane type-1 matrix metalloproteinase in cancer invasion and angiogenesis. Cancer Sci. 2003;94:569–574.
[CrossRef] [PubMed]PeiD, WeissSJ. Furin-dependent intracellular activation of the human stromelysin-3 zymogen. Nature. 1995;375:244–247.
[CrossRef] [PubMed]PeiD, WeissSJ. Transmembrane-deletion mutants of the membrane-type matrix metalloproteinase-1 process progelatinase A and express intrinsic matrix-degrading activity. J Biol Chem. 1996;271:9135–9140.
[CrossRef] [PubMed]RemacleA, MurphyG, RoghiC. Membrane type I-matrix metalloproteinase (MT1-MMP) is internalised by two different pathways and is recycled to the cell surface. J Cell Sci. 2003;116:3905–3916.
[CrossRef] [PubMed]WuYI, MunshiHG, SenR, et al. Glycosylation broadens the substrate profile of membrane type 1 matrix metalloproteinase. J Biol Chem. 2004;279:8278–8289.
[CrossRef] [PubMed]ItohY, SeikiM. MT1-MMP: an enzyme with multidimensional regulation. Trends Biochem Sci. 2004;29:285–289.
[CrossRef] [PubMed]ZuckerS, HymowitzM, ConnerCE, DiYanniEA, CaoJ. Rapid trafficking of membrane type 1-matrix metalloproteinase to the cell surface regulates progelatinase a activation. Lab Invest. 2002;82:1673–1684.
[CrossRef] [PubMed]HolmbeckK, BiancoP, YamadaS, Birkedal-HansenH. MT1-MMP: a tethered collagenase. J Cell Physiol. 2004;200:11–19.
[CrossRef] [PubMed]ZhongZD, HammaniK, BaeWS, DeClerckYA. NF-Y and Sp1 cooperate for the transcriptional activation and cAMP response of human tissue inhibitor of metalloproteinases-2. J Biol Chem. 2000;275:18602–18610.
[CrossRef] [PubMed]YamamotoM, SatoN, TajimaH, et al. Induction of human thioredoxin in cultured human retinal pigment epithelial cells through cyclic AMP-dependent pathway: involvement in the cytoprotective activity of prostaglandin E1. Exp Eye Res. 1997;65:645–652.
[CrossRef] [PubMed]AlexanderJP, AcottTS. Involvement of the Erk-MAP kinase pathway in TNFalpha regulation of trabecular matrix metalloproteinases and TIMPs. Invest Ophthalmol Vis Sci. 2003;44:164–169.
[CrossRef] [PubMed]GargTK, ChangJY. Oxidative stress causes ERK phosphorylation and cell death in cultured retinal pigment epithelium: prevention of cell death by AG126 and 15-deoxy-delta 12, 14-PGJ2. BMC Ophthalmol. 2003;3:5.
[CrossRef] [PubMed]MorrisonCJ, ButlerGS, BiggHF, RobertsCR, SolowayPD, OverallCM. Cellular activation of MMP-2 (gelatinase A) by MT2-MMP occurs via a TIMP-2-independent pathway. J Biol Chem. 2001;276:47402–47410.
[CrossRef] [PubMed]JacobsonSG, CideciyanAV, BennettJ, KingsleyRM, SheffieldVC, StoneEM. Novel mutation in the TIMP3 gene causes Sorsby fundus dystrophy. Arch Ophthalmol. 2002;120:376–379.
[CrossRef] [PubMed]LangtonKP, McKieN, CurtisA, et al. A novel tissue inhibitor of metalloproteinases-3 mutation reveals a common molecular phenotype in Sorsby’s fundus dystrophy. J Biol Chem. 2000;275:27027–27031.
[PubMed]